Jolla制药

LJPC NASDAQ
6.13
-0.32
-4.96%
盘后: 6.13 0 0.00% 16:50 05/17 EDT
开盘
6.39
昨收
6.45
最高
6.50
最低
6.13
成交量
41.64万
成交均量(3M)
59.21万
52周最高
38.39
52周最低
5.01
换手率
1.54%
市值
1.66亿
分时
5日
1月
3月
1年
5年

评论

暂无数据

相关股票

微牛行情栏目提供Jolla制药 LJPC股票价格,Jolla制药股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH). It has initiated a Phase III trial of LJPC-501 for the treatment of CRH, called the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS) Phase III trial. LJPC-401 is its formulation of synthetic human hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is its next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections, as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
展开 >

最近浏览

名称
价格
涨跌幅